Share This

PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention
NEW TAIPEI CITY , May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International ...
2024-05-11T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ribobay Pharma boosts CRDMO offerings with Cytiva's first FlexFactory platform for oligonucleotides
FlexFactory platform for oligonucleotides, an integrated solution to boost efficiency and speed of pharmaceutical manufacturing to meet market demand SHANGHAI , May 10, 2024 /PRNewswire/ -- ...
2024-05-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
The biotech company continues to offer hope to systemic lupus erythematosus  ( SLE) patients globally by sharing the latest developments of its proprietary novel fusion protein drug Telitacicept ...
2024-05-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval
CHENGDU, China , May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, ...
2024-05-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost
Adalimumab-aaty will be priced at an 85% discount to HUMIRA ® (adalimumab) Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients ...
2024-05-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Origin Agritech Receives GMO Safety Certificate for its Triple Stack Maize
Commercial Rollout to Begin Shortly ...
2024-05-09T    Agriculture   Biotechnology   Computer/Electronics 
Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology
First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias. ...
2024-05-09T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic ...
2024-05-09T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic ...
2024-05-09T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
SAN FRANCISCO and SUZHOU, China , May 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
2024-05-09T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.